Yang L, Wang Y, Zuo Y
Arch Dermatol Res. 2025; 317(1):303.
PMID: 39853516
DOI: 10.1007/s00403-024-03760-0.
Gandarillas S, Berger A, Stephenson R, Mehregan D, Dasgeb B
Int J Dermatol. 2024; 64(2):399-401.
PMID: 39592443
PMC: 11771636.
DOI: 10.1111/ijd.17563.
Dhaouadi T, Riahi A, Ben Abdallah T, Gorgi Y, Sfar I
Int J Immunopathol Pharmacol. 2024; 38:3946320241296903.
PMID: 39442009
PMC: 11503847.
DOI: 10.1177/03946320241296903.
Gandarillas S, Newland E, Toppmeyer D, Stephenson R, Denzin L, Dasgeb B
Front Med (Lausanne). 2024; 10:1288844.
PMID: 38259857
PMC: 10800809.
DOI: 10.3389/fmed.2023.1288844.
de Nicolas-Ruanes B, Ballester-Martinez A, Garcia-Mouronte E, Berna-Rico E, Azcarraga-Llobet C, Fernandez-Guarino M
Int J Mol Sci. 2023; 24(23).
PMID: 38069109
PMC: 10706090.
DOI: 10.3390/ijms242316786.
Role of Human Leukocyte Antigen Class II in Antibody-Mediated Skin Disorders.
Sernicola A, Mazzetto R, Tartaglia J, Ciolfi C, Miceli P, Alaibac M
Medicina (Kaunas). 2023; 59(11).
PMID: 38003999
PMC: 10673328.
DOI: 10.3390/medicina59111950.
Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature.
Sonego B, Zelin E, Zalaudek I, Di Meo N
Dermatol Reports. 2023; 15(3):9676.
PMID: 37822982
PMC: 10563024.
DOI: 10.4081/dr.2023.9676.
Environmental factors in autoimmune bullous diseases with a focus on seasonality: new insights.
DAstolto R, Quintarelli L, Corra A, Caproni M, Fania L, Di Zenzo G
Dermatol Reports. 2023; 15(3):9641.
PMID: 37753233
PMC: 10518530.
DOI: 10.4081/dr.2023.9641.
Bullous Pemphigoid and Human Leukocyte Antigen (HLA)-DQA1: A Systematic Review.
Hesari R, Thibaut D, Schur N, Thoutireddy S, Witcher R, Julian E
Cureus. 2023; 15(6):e39923.
PMID: 37416040
PMC: 10319936.
DOI: 10.7759/cureus.39923.
Bullous Pemphigoid Associated With Dipeptidyl Peptidase-4 Inhibitors: A Case Report and Review of Current Evidence.
Hadjkacem F, Frikha H, Boujelben K, Chaari C, Mnif E, Masmoudi A
Hosp Pharm. 2023; 58(4):357-362.
PMID: 37360199
PMC: 10288458.
DOI: 10.1177/00185787231151861.
Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database.
Harano Y, Mitamura Y, Jiang P, Fujita T, Babazono A
J Diabetes Investig. 2023; 14(6):756-766.
PMID: 36897510
PMC: 10204174.
DOI: 10.1111/jdi.14004.
Dipeptidyl Peptidase-4 Inhibitor-Related Bullous Pemphigoid: Clinical, Laboratory, and Histological Features, and Possible Pathogenesis.
Hung C, Chang Y, Wang W
Int J Mol Sci. 2022; 23(22).
PMID: 36430582
PMC: 9692886.
DOI: 10.3390/ijms232214101.
What's new in the pathogeneses and triggering factors of bullous pemphigoid.
Ujiie H
J Dermatol. 2022; 50(2):140-149.
PMID: 36412277
PMC: 10098684.
DOI: 10.1111/1346-8138.16654.
Clinical Phenotypes and the Clinical Course of Bullous Pemphigoid Receiving Dipeptidyl Pepitidase-4 Inhibitor Treatment: An Analysis of Cases in a Single Japanese Center.
Nakagawa Y, Toyoda M, Saito N, Kaneyama N, Shimizu T, Mabuchi T
Intern Med. 2022; 62(12):1715-1722.
PMID: 36328578
PMC: 10332970.
DOI: 10.2169/internalmedicine.0815-22.
Type XVII collagen: Relevance of distinct epitopes, complement-independent effects, and association with neurological disorders in pemphigoid disorders.
Opelka B, Schmidt E, Goletz S
Front Immunol. 2022; 13:948108.
PMID: 36032160
PMC: 9400597.
DOI: 10.3389/fimmu.2022.948108.
A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets.
Afarideh M, Borucki R, Werth V
J Clin Med. 2022; 11(10).
PMID: 35628982
PMC: 9146139.
DOI: 10.3390/jcm11102856.
The Immunogenetics of Autoimmune Blistering Diseases.
Kneiber D, Kowalski E, Amber K
Adv Exp Med Biol. 2022; 1367:173-212.
PMID: 35286697
DOI: 10.1007/978-3-030-92616-8_8.
Molecular Basis for Global Incidence of Pemphigoid Diseases and Differences in Phenotypes.
Ahmed A, Anwar S, Reche P
Front Immunol. 2022; 13:807173.
PMID: 35126393
PMC: 8813746.
DOI: 10.3389/fimmu.2022.807173.
Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation.
Kridin K, Avni O, Damiani G, Tzur Bitan D, Onn E, Weinstein O
Arch Dermatol Res. 2022; 315(1):33-39.
PMID: 35032198
DOI: 10.1007/s00403-021-02317-9.
Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin.
Chouchane K, Di Zenzo G, Pitocco D, Calabrese L, De Simone C
J Transl Med. 2021; 19(1):520.
PMID: 34930319
PMC: 8691092.
DOI: 10.1186/s12967-021-03192-8.
